Cipla Limited (BOM:500087)
India
· Delayed Price · Currency is INR | Market Cap | 1.06T |
| Revenue (ttm) | 279.67B |
| Net Income (ttm) | 45.46B |
| Shares Out | n/a |
| EPS (ttm) | 56.25 |
| PE Ratio | 23.21 |
| Forward PE | 23.89 |
| Dividend | 16.00 (1.30%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 51,128 |
| Average Volume | 164,793 |
| Open | 1,320.15 |
| Previous Close | 1,294.75 |
| Day's Range | 1,299.05 - 1,320.15 |
| 52-Week Range | 1,165.55 - 1,672.20 |
| Beta | n/a |
| RSI | 65.00 |
| Earnings Date | May 13, 2026 |
About Cipla
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obe... [Read more]
Financial Performance
In fiscal year 2025, Cipla's revenue was 272.67 billion, an increase of 6.78% compared to the previous year's 255.37 billion. Earnings were 52.73 billion, an increase of 27.93%.
Financial StatementsNews
Cohance Lifesciences Hits 20% Upper Circuit After Appointing Former Cipla CEO Umang Vohra as Chairman and Group CEO
Shares of Cohance Lifesciences hit the 20% upper circuit, surging ₹72 to ₹432.10 on the NSE as of 9:38 AM IST on Monday, April 27, after the company announced the…
Cipla faces $100 million revenue risk as USFDA alert delays restart beyond FY27, says Macquarie
Cipla may face a significant setback to its US growth trajectory after a regulatory action impacted supplies of a key product, with brokerage firm Macquarie flagging a potential revenue risk…
Cipla Shares Fall 3% as Partner Unit Gets FDA Import Alert, Lanreotide Revenue at Risk
Cipla shares dropped 2.93% or ₹38.20 to ₹1,267.70 on the NSE as of 9:25 AM IST on April 24, touching an intraday low of ₹1,254.10 in early trade, after it…
Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup
A busy morning for broker calls with Infosys drawing the most divided analyst opinion after its Q4 FY26 results, Dr Reddy's receiving back-to-back downgrades on the Semaglutide opportunity, Cipla gett...
Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more
Indian equity benchmarks ended lower on Thursday, April 23, 2026, with the NIFTY 50 closing at 24,173.05, down 205.05 points (-0.84%). Despite the broader market weakness, select stocks managed to…
Cipla gets USFDA nod for first AB-rated generic of Ventolin HFA
Cipla Limited on April 23 announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Albuterol…
Cipla receives USFDA approval for first AB-rated generic of Ventolin HFA
Cipla Limited has announced that its wholly owned subsidiary, Cipla USA Inc., has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug…
Pharma sector stocks today, April 22: Natco Pharma up 1.4%, Lupin falls 1.01%, Cipla down 0.73%
The Indian pharmaceutical sector opened on a mixed note on April 22, 2026. The NIFTY PHARMA Index was trading at 22,403.2, down 0.2%, while the S&P BSE Healthcare Index stood…
Cipla receives two inspectional observations from USFDA at Goa facility
Cipla has announced that the United States Food and Drug Administration (USFDA) conducted an inspection at its manufacturing facility in Verna, Goa, India. The inspection, which took place from 6th…
Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77%
Pharmaceutical sector stocks traded mostly lower in early trade on Monday, April 13, 2026, with most counters under pressure. The S&P BSE Healthcare Index declined 0.88% to 42,246.47, while the…
Cipla Gets FDA Approval For Generic Nintedanib Capsules
(RTTNews) - Cipla USA Inc. the wholly owned subsidiary of Cipla Limited (500087, CIPLA) announced that it has received final approval from U.S. FDA for Abbreviated New Drug Application or ANDA for Nin...
Cipla appoints new senior management personnel amid leadership changes
Cipla has announced significant changes in its senior management team as part of a leadership transition. Effective 1st April 2026, Mr Achin Gupta will take charge as the Managing Director…
Cipla, Bajaj Finserv & more: Top stocks to watch today
Analysts have adjusted targets for several companies, with UBS neutral on Cipla citing supply headwinds despite a healthy pipeline. Motilal Oswal initiated coverage on Bajaj Finserv with a neutral rat...
Cipla's Global Chief Scientific Officer Pradeep Bhadauria resigns
Cipla has announced the resignation of Mr Pradeep Bhadauria, the Global Chief Scientific Officer and a member of the Management Council. Bhadauria, who is also an employee of Cipla USA…
Nifty 50 top losers today, March 24: Coal India, Power Grid, Adani Enterprises, Sun Pharma and Cipla
Indian equity benchmarks ended on a strong note on March 24, with the Nifty closing above the 22,900 mark. The Sensex gained 1,372.06 points (1.89%) to settle at 74,068.45, while…
Nifty 50 top losers today, March 18: Hindustan Unilever, Coal India, Cipla, NTPC and more
The Indian equity markets ended lower on March 18, 2026, with benchmark indices witnessing selling pressure across key sectors. The Nifty 50 closed at 23,777.80, down 196.65 points or 0.83%,…
Nifty 50 top losers today, March 17: Wipro, Cipla, Infosys, Tata Consumer Products, ITC and more
Indian benchmark indices ended lower on March 17, with the Nifty 50 closing at 23,581.15, down 172.35 points or 0.74%. Weakness across IT, FMCG and financial stocks weighed on the…
FENC Settles Litigation with Cipla Over PEDMARK Generic Entry
FENC Settles Litigation with Cipla Over PEDMARK Generic Entry
Should you buy, hold, or sell Cipla shares? Here’s what Morgan Stanley recommends
Wednesday, March 11 Shares of Cipla were trading around Rs 1,327.80, down 0.43% in early trade on Wednesday after concerns emerged over supply disruptions in one of the company’s key…
Top Stocks To Buy/Sell Today: HAL, Cipla, Godrej Properties, Aster DM, Ultratech Cement, Adani Ports besides others in focus
Several stocks are expected to remain in focus today following key order wins, regulatory approvals, capacity expansions, mergers and corporate developments announced by companies. Hindustan Aeronauti...
Cipla forms 60:40 JV with Kemwell Biopharma to develop and commercialise biologic products
Cipla Limited has entered into a 60:40 joint venture agreement with Kemwell Biopharma Private Limited on March 2, 2026, for...
Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09%
The Indian pharmaceutical sector showed mixed performance on February 27, 2026, during early morning trading hours. Data from around 9:24...
Cipla shares fall over 2% after USFDA classifies Greece facility inspection as OAI
Shares of Cipla declined more than 2% in early trade after the company disclosed that the United States Food and...
Top stocks to watch today – February 23: Axis Bank, UPL, Vedanta, Adani Ports, SBI Life, NHPC, IDFC First, Cipla and more
Indian markets are expected to react to a mix of corporate developments, regulatory actions, fund-raising plans, order wins and policy...
Nifty 50 top losers today, Feb 12: Cipla, Adani Enterprises, Maruti Suzuki India, INDIGO, Adani Ports and more
Indian equity indices ended lower on February 12, with the Nifty closing below the 25,850 mark amid broad-based selling pressure....